middle.news
How Dimerix’s PARASOL Data Could Accelerate Kidney Disease Drug Approval
8:45am on Wednesday 8th of October, 2025 AEDT
•
Biotechnology
Read Story
How Dimerix’s PARASOL Data Could Accelerate Kidney Disease Drug Approval
8:45am on Wednesday 8th of October, 2025 AEDT
Key Points
PARASOL data supports proteinuria endpoints at 104 weeks for ACTION3 study
Potential link found between 12-month proteinuria levels and kidney failure risk
Dimerix to engage FDA on accelerated approval strategies using early endpoints
Blinded analysis of ACTION3 data pending to confirm statistical assumptions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE